First-pass extracted concept

AAV capsid engineering

Candidate: concept label2 source documents8 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

capsid-engineering strategies

Extracted Explainers

What the tool is doing

AAV capsid engineering is described as one of the strategies discussed to improve gene therapy efficacy for joint disease.

Source 1DOI

What problem it solves

It is framed as a response to delivery barriers affecting intra-articular AAV use.

Source 1DOI

Evidence Snippets

This review provides an overview of the current paradigms of treatment with regards to joint disease, elaborates on the AAV delivery barriers related to application in treating joint diseases, and discusses strategies to improve gene therapy efficacy, including AAV capsid engineering...

Evidence 1Source 1DOIprovenance

Here, we summarize recent capsid-engineering strategies designed to improve on-target delivery and reduce vector dose requirements.

Evidence 2Source 2DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025PPRDOI

1 evidence snippet 1 linked claim Claim 1

Source 2primary paper2025MEDDOI PubMed

1 evidence snippet 7 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1benchmark summarysupports2025Source 2DOI PubMed

Across tissues, engineered AAV capsids routinely show multi-fold improvements in potency and biodistribution relative to natural serotypes.

Claim 2delivery strategysupports2025Source 2DOI PubMed

Suprachoroidal and laterally spreading subretinal vectors expand posterior-segment coverage in the retina.

Claim 3engineering goalsupports2025Source 2DOI PubMed

Recent AAV capsid-engineering strategies are designed to improve on-target delivery and reduce vector dose requirements.

Claim 4mechanism strategysupports2025Source 2DOI PubMed

In the retina, intravitreal performance improves by fine-tuning HSPG interactions to facilitate ILM traversal.

Claim 5performance claimsupports2025Source 2DOI PubMed

For muscle, next-generation myotropic and liver-detargeted capsids enable uniform skeletal and cardiac transduction at substantially lower intravenous doses.

Claim 6problem statementsupports2025Source 2DOI PubMed

Clinically used AAV capsids often have limited potency in human CNS, muscle, and retina tissues, which can require high systemic doses and increase cost and toxicity risk.

Claim 7strategy overviewsupports2025Source 1DOI

Strategies discussed to improve AAV gene therapy efficacy for joint disease include capsid engineering, small molecular-assisted delivery, promoter optimization, and immune-response mitigation.

Quoted textsource-backed

This review provides an overview of the current paradigms of treatment with regards to joint disease, elaborates on the AAV delivery barriers related to application in treating joint diseases, and discusses strategies to improve gene therapy efficacy, including AAV capsid engineering, small molecular-assisted AAV delivery, optimizing tissue-specific or inflammation-inducible promoters, as well as strategies to mitigate immune responses to AAV.

Claim 8translational implicationsupports2025Source 2DOI PubMed

Advances in AAV capsid engineering outline a translational path toward safer, lower-dose gene therapies with improved precision and clinical feasibility.